In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...
All content for Talking Rheumatology Research is the property of British Society for Rheumatology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...
Ep 38. Is risankizumab safe and effective for active psoriatic arthritis? Results from the KEEPsAKE 2 study
Talking Rheumatology Research
7 minutes
2 years ago
Ep 38. Is risankizumab safe and effective for active psoriatic arthritis? Results from the KEEPsAKE 2 study
Dr Andrew Östör joins Dr Marwan Bukhari to discuss their article, chosen as the June Editor's Choice article, which evaluates the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one or more conventional synthetic DMARDs (csDMARD-IR).Listen now to hear the findings and what this means for future clinical practice! You can read this article [https://doi.org/10.1093/r...
Talking Rheumatology Research
In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...
